STOCK TITAN

Xenetic Biosciences (XBIO) Stock Price, News & Analysis

XBIO NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
54 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
-48.7% close of September 16, 2026
1-year change
-39.4% closing prices, November 20, 2025 to November 20, 2026
1-month change
-30% closing prices, October 20, 2026 to November 20, 2026

Company Description

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing immuno-oncology technologies for difficult to treat cancers. According to the company’s public disclosures, Xenetic is developing a proprietary DNase-based oncology platform designed to improve outcomes of existing cancer treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are described as being involved in cancer progression and in the progression of many human cancers.

Core focus: DNase platform in oncology

Xenetic states that its platform centers on systemic recombinant human DNase I, with programs aimed at using DNase I as an adjunctive therapy alongside chemotherapy, immunotherapies, CAR T-cell therapies and other established cancer treatments. Company communications describe a focus on pancreatic carcinoma, colorectal cancer, large B cell lymphoma, osteosarcoma, Ewing sarcoma and other locally advanced or metastatic solid tumors, where there is significant unmet medical need.

The company reports that it is advancing its DNase-based technology toward Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Xenetic has also highlighted preclinical proof-of-concept work combining DNase I with chemotherapy, immunotherapies and CAR-T therapies in hematologic and solid tumor models, as well as metastatic cancer models.

Mechanism: Targeting neutrophil extracellular traps (NETs)

In its descriptions of the DNase platform, Xenetic explains that NETs are web-like structures composed of extracellular chromatin coated with histones and other proteins, expelled by activated neutrophils into the tumor microenvironment and blood. The company reports that these NETs are associated with cancer spread, local and systemic immunosuppression, immune escape, resistance to therapy and other hallmarks of cancer biology.

Xenetic’s disclosures state that reduction of NET burden via its proprietary recombinant human DNase I has been shown in preclinical animal models to improve the efficacy of immunotherapy, adoptive cell therapy and chemotherapy. In particular, studies conducted in collaboration with academic partners are described as showing that co-administration of DNase I with CAR-T cells can reduce tumor burden, decrease metastatic lesions, extend survival compared to CAR-T monotherapy, and enhance CAR-T and endogenous T-cell infiltration into tumors while mitigating an immunosuppressive tumor microenvironment.

Systemic DNase I candidate XBIO-015 and CAR-T combinations

The company identifies XBIO-015 as its systemic DNase I candidate. Public statements indicate that XBIO-015 is in preclinical development in combination with CAR T-cell therapy for both hematologic and solid tumors. Xenetic has reported research conducted at The Scripps Research Institute and in the lab of an institute investigator, using lymphoma, metastatic melanoma and leukemia models, where co-administration of DNase I with CAR-T cells was associated with reduced tumor burden, fewer metastatic lesions and extended survival versus CAR-T cell monotherapy.

Based on these results, Xenetic has announced that its research and development collaboration has been expanded to include additional models of lymphoma and leukemia to further validate DNase I data generated to date. The company characterizes this work as part of a broader DNase-based oncology platform that targets NETs to potentially enhance the performance of CAR-T and other therapies.

Exploratory and investigator-initiated clinical studies

Xenetic’s disclosures describe a strategic focus on exploratory, investigator-initiated clinical studies with institutional partners. The company has entered into a Clinical Trial Services Agreement with PeriNess Ltd., under which PeriNess is expected to lead regulatory approval, operational execution and management of potential exploratory studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.

According to company announcements, PeriNess has informed Xenetic of an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first line treatment of unresectable, locally advanced or metastatic pancreatic cancer at Bnei Zion Medical Center, with patient dosing commenced. The exploratory study is described as evaluating safety, biomarker response, pharmacokinetics and clinical activity of DNase I in combination with FOLFIRINOX, with clinical activity assessed by objective response rate and progression-free survival.

Xenetic has also reported that PeriNess entered into a Clinical Study Agreement for an exploratory study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma, to be conducted at the Tel Aviv Sourasky Medical Center. The primary objective is described as exploring safety and tolerability of DNase I in combination with anti-CD19 CAR T therapy in subjects with stable or progressive large B-cell lymphoma in an adjuvant setting, with secondary objectives including response rate, duration of response and overall survival.

Preclinical data and scientific communications

Across its public updates, Xenetic notes that preclinical proof-of-concept studies combining DNase I with chemotherapy, immunotherapies and CAR-T therapy in hematological and solid tumor and metastatic cancer models have been completed. The company indicates that, building on this proof-of-concept work, its program has advanced to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial.

Xenetic has also highlighted scientific dissemination of its work. For example, the company referenced a poster presentation titled “DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma” at a Society for Immunotherapy of Cancer (SITC) Spring Scientific Cell Therapy Meeting, and a related virtual investor segment discussing positive preclinical data.

Collaborations and royalty revenue

In financial updates, Xenetic has pointed to collaborations with academic and clinical partners, including The Scripps Research Institute and PeriNess, as central to generating data that may guide development and regulatory strategies for its DNase technology. The company has also disclosed royalty revenue related to a sublicense agreement with Takeda Pharmaceuticals Co. Ltd., with increases in revenue attributed to royalty income recognized from certain countries during reported periods.

These collaborations and licensing arrangements are presented by the company as part of its approach to advancing its DNase-based oncology platform while managing internal resources.

Corporate and regulatory profile

According to its SEC filings, Xenetic Biosciences, Inc. is incorporated in Nevada and its common stock, with a par value of $0.001 per share, trades on The Nasdaq Stock Market under the symbol XBIO. The company has filed a shelf registration statement on Form S-3 and has conducted underwritten offerings of common stock, with stated uses of proceeds including working capital, general corporate purposes and advancement of the DNase technology.

Xenetic has also filed definitive proxy materials describing its annual meeting of stockholders, director elections, auditor ratification and advisory votes on executive compensation. The company has used Form 8-K filings to furnish press releases regarding quarterly financial results and to report material definitive agreements, such as underwriting agreements for public offerings.

Position within the pharmaceutical preparation manufacturing sector

Within the broader pharmaceutical preparation manufacturing industry, Xenetic describes itself as a company focused on immuno-oncology, with an emphasis on NET-targeting DNase technology as a potential adjunct to established cancer regimens. Rather than detailing a broad product line, the company’s public communications center on a specific platform approach and on moving its systemic DNase programs from preclinical and exploratory clinical work toward formal early-stage clinical development.

Stock Performance

$1.40
-9.09%
-0.14
Last updated: at
-39.4%
Performance 1 year
2.3M
Shares outstanding As of November 6, 2026.

Xenetic Biosciences (XBIO) closed at $1.40 on November 20, 2026. Over the past 12 months, the price has lost 39.4%.

See what a $1,000 investment in XBIO would be worth today

Average down calculator for XBIO

XBIO Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Xenetic Biosciences has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings. View all XBIO news →

Financial Highlights

Xenetic Biosciences generated $3.0M in revenue in FY2025, operating income reached -$2.8M (-95.2% operating margin), and net income was -$2.7M, reflecting a -90.1% net profit margin. Diluted earnings per share stood at -$1.58. The company generated -$2.3M in operating cash flow. The current ratio was 8.32, measuring current assets divided by current liabilities.

$3.0M
Revenue (FY2025)
-$2.7M
Net Income (FY2025)
-$2.3M
Operating Cash Flow

Upcoming Events

DEC
12
December 12, 2026 - December 12, 2026 Marketing

ASH oral presentation

Oral presentation on CAR T resistance at 68th ASH Meeting in New Orleans; Alexey Stepanov presenting 4:00–4:15 PM Central Time.
Q1
2027
Q1 2027 Corporate

Santersus acquisition close

Expected closing of Xenetic's acquisition of Santersus in Q1 2027, subject to shareholder approval and customary closing conditions.
Q2
2027
Q2 2027 Clinical

Initial efficacy data

Initial efficacy data expected in Q2 2027 from Phase I DNase I plus anti-CD19 CAR T-cell study in large B-cell lymphoma.

Xenetic Biosciences has 3 upcoming scheduled events. The next event, "ASH oral presentation", is scheduled for December 12, 2026 (in 21 days). Investors can track these dates to stay informed about potential catalysts that may affect the XBIO stock price.

Short Interest History

Last 12 Months

Short interest in Xenetic Biosciences (XBIO) currently stands at 37.0 thousand shares, up 237.7% from the previous reporting period, representing 1.9% of the float. Since November 2025, short interest has increased by 88.0%.

Days to Cover History

Last 12 Months

Days to cover for Xenetic Biosciences (XBIO) currently stands at 1.2 days, up 18% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 3.1 days.

XBIO Company Profile & Sector Positioning

Xenetic Biosciences (XBIO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing XBIO often look at related companies in the same sector, including Aprea Therapeutics, Inc. (APRE), NuCana plc (NCNA), Imunon, Inc. (IMNN), Liminatus Pharma, Inc. (LIMN), and Azitra Inc (AZTR). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate XBIO's relative position within its industry.

Frequently Asked Questions

The current stock price of Xenetic Biosciences (XBIO) is $1.40 as of November 20, 2026.

The market cap of Xenetic Biosciences (XBIO) is approximately $3.3M. Learn more about what market capitalization means .

The FY2025 revenue of Xenetic Biosciences (XBIO) is $3.0M, from its most recent completed fiscal year.

The FY2025 net income of Xenetic Biosciences (XBIO) is -$2.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Xenetic Biosciences (XBIO) is -$1.58 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Xenetic Biosciences (XBIO) is -$2.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Xenetic Biosciences (XBIO) is -90.1% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Xenetic Biosciences (XBIO) is -95.2% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of Xenetic Biosciences (XBIO), current assets divided by current liabilities, was 8.32 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Xenetic Biosciences (XBIO) is -$2.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

Xenetic Biosciences, Inc. is a biopharmaceutical company whose public disclosures describe a focus on advancing immuno-oncology technologies for difficult to treat cancers. Its main platform is based on recombinant human DNase I designed to target neutrophil extracellular traps (NETs) and to be used alongside established cancer treatments.

Xenetic’s DNase-based oncology platform, as described by the company, is designed to improve outcomes of existing treatments, including immunotherapies, by targeting NETs that are involved in cancer progression. The company reports that reducing NET burden with its proprietary recombinant human DNase I has improved efficacy of immunotherapy, adoptive cell therapy and chemotherapy in preclinical models.

Company communications highlight pancreatic carcinoma and other locally advanced or metastatic solid tumors as primary indications. Xenetic also references work in hematologic and solid tumor models, including lymphoma, metastatic melanoma, leukemia, colorectal cancer, large B cell lymphoma, osteosarcoma and Ewing sarcoma in preclinical or exploratory clinical contexts.

According to Xenetic, systemic recombinant human DNase I is intended to degrade NETs in the tumor microenvironment and blood. By reducing NET burden, the company reports that DNase I has enhanced the performance of immunotherapies, CAR-T cell therapies and chemotherapy in preclinical cancer models.

XBIO-015 is described by Xenetic as its systemic DNase I candidate. The company reports that XBIO-015 is in preclinical development in combination with CAR T-cell therapy for both hematologic and solid tumors, with studies suggesting benefits when co-administered with CAR-T cells in certain lymphoma, metastatic melanoma and leukemia models.

Xenetic states that it is advancing its DNase-based technology toward Phase 1 clinical development for pancreatic carcinoma and other locally advanced or metastatic solid tumors. It has also reported exploratory, investigator-initiated clinical studies of systemic DNase I in combination with FOLFIRINOX in unresectable, locally advanced or metastatic pancreatic cancer and with anti-CD19 CAR T cells in large B cell lymphoma.

Public announcements identify The Scripps Research Institute as a collaborator on preclinical studies combining systemic DNase I with CAR T-cell therapies, and PeriNess Ltd. as a partner under a Clinical Trial Services Agreement. PeriNess is described as leading regulatory approval, operational execution and management of potential exploratory, investigator-initiated DNase studies in Israeli medical centers.

In its financial results, Xenetic reports revenue that includes royalty income related to a sublicense agreement with Takeda Pharmaceuticals Co. Ltd. The company has noted increases in royalty revenue from certain countries during specific quarters, alongside its ongoing research and development spending.

SEC filings state that Xenetic Biosciences, Inc.’s common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market under the trading symbol XBIO.

Xenetic uses Form 8-K to report material events such as quarterly financial results and underwriting agreements, Form S-3 for shelf registration of securities, and a definitive proxy statement on Schedule 14A for its annual meeting of stockholders. These filings, along with press releases, provide information on its DNase platform, collaborations, offerings and corporate governance matters.